抗血管内皮生长因子治疗的视网膜中央静脉阻塞中黄斑水肿消退模式与视觉结局的关联:Lucentis、Eylea、Avastin 静脉阻塞试验的事后分析
该事后分析基于前瞻性、三臂、双盲、随机非劣效性 LEAVO 试验,评估 425 只视网膜中央静脉阻塞相关黄斑水肿眼接受抗血管内皮生长因子治疗后,52 周和 100 周黄斑液体消退模式与 100 周最佳矫正视力的关联。结果显示,100 周持续黄斑水肿较干性黄斑和复发性黄斑水肿视力更差,贝伐珠单抗组持续湿性黄斑比例高于阿柏西普和雷珠单抗组。
要点
- 100 周持续黄斑水肿眼视力较干性黄斑差 10.98 个 ETDRS 字母(95%CI -16.19 至 -5.76,P<.001)。
- 100 周持续黄斑水肿眼视力较复发性黄斑水肿差 5.39 个字母(95%CI -10.15 至 -0.64,P=.03)。
- 贝伐珠单抗组持续湿性黄斑比例高于阿柏西普组(18.6% vs 5.2%,差值 13.3%,P<.001)和雷珠单抗组(8%,差值 10.5%,P=.01)。
核心结论
- 这些发现提示应努力维持黄斑持续无液体以达最佳视力结局。
研究设计与样本
- 前瞻性、三臂、双盲、随机非劣效性 LEAVO 试验的事后分析,纳入 425 只眼(425 名参与者),随机接受玻璃体腔内阿柏西普 2.0 mg/0.05 mL、贝伐珠单抗 1.25 mg/0.05 mL 或雷珠单抗 0.5 mg/0.05 mL,随访 100 周。
主要发现
- 截至 100 周,117 只眼(28.5%)持续干性,44 只眼(10.7%)持续湿性(伴黄斑水肿),250 只眼(60.8%)为复发性黄斑水肿。
- 100 周持续黄斑水肿与干性黄斑相比视力更差(校正差值 -10.98 个 ETDRS 字母;95%CI -16.19 至 -5.76;P<.001),与复发性黄斑水肿相比亦更差(校正差值 -5.39 个字母;95%CI -10.15 至 -0.64;P=.03)。
- 52 周时持续黄斑水肿者 100 周最佳矫正视力较干性黄斑者差(校正差值 -7.39;95%CI -11.72 至 -3.05;P<.001),较复发性黄斑水肿者差(校正差值 -3.92;95%CI -8.05 至 0.20;P=.06)。
- 100 周时贝伐珠单抗组持续湿性黄斑眼数多于阿柏西普组(26/140 [18.6%] vs 7/134 [5.2%];差值 13.3%;95%CI 5.9 至 20.8;P<.001)和雷珠单抗组(11/137 [8%];差值 10.5%;95%CI 2.7 至 18.4;P=.01)。
关键数值与推荐
- 持续黄斑水肿定义为 52 周和 100 周时中央亚区厚度≥320 μm,持续干性黄斑定义为中央亚区厚度<320 μm,复发性黄斑水肿为不符合持续干性或湿性标准者。
- 中央亚区厚度缺失时采用最近一次中间访视数据向前填充。
临床怎么用
- 作者认为应努力维持黄斑持续无液体以达最佳视力结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is unclear how visual outcomes vary between patterns of macular edema (ME) resolution in eyes with central retinal vein occlusion (CRVO). OBJECTIVE: To assess best-corrected visual acuity (BCVA) outcomes at 100 weeks based on macular fluid resolution patterns by 52 and 100 weeks among patients receiving anti-vascular endothelial growth factor therapy for CRVO-related ME. DESIGN, SETTING, AND PARTICIPANTS: Post hoc analysis of the prospective, 3-arm, double-masked, randomized noninferiority trial Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO), which evaluated intravitreal aflibercept (2.0 mg/0.05 mL), bevacizumab (1.25-mg/0.05 mL), or ranibizumab (0.5 mg/0.05 mL) over 100 weeks in adult patients (18 years and older) with CRVO-related ME with BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) letter score of 19 to 78 in the study eye (approximate Snellen equivalent, 20/400 to 20/32, respectively) from December 2014 to December 2016 at 44 UK National Health Service ophthalmology departments. A total of 140 of 154 eyes were randomized to aflibercept, 144 of 154 randomized to bevacizumab, and 141 of 155 randomized to ranibizumab. Data were analyzed from January 2019 to March 2019. EXPOSURES: Persistent ME included eyes with central subfield thickness (CST) 320 μm or greater, and persistently dry macula (no ME) included eyes with CST less than 320 μm at 52 and 100 weeks. Recurrent ME included eyes that did not meet the criteria for persistently dry or wet. If CST was missing, the closest intervening visit was carried forward. MAIN OUTCOMES AND MEASURES: Adjusted mean BCVA at 100 weeks. RESULTS: The mean (SD) age of the 425 included participants was 69.2 (12.7) years, and 243 participants (57.2%) were men. A total of 425 eyes from 425 participants were included. By 100 weeks, 117 eyes (28.5%) were persistently dry, 44 (10.7%) were persistently wet (with ME), and 250 (60.8%) had recurrent ME. Persistent ME at 100 weeks was associated with worse VA compared with dry macula (adjusted difference, -10.98 ETDRS letters; 95% CI, -16.19 to -5.76; P < .001) and recurrent ME (adjusted difference, -5.39 letters; 95% CI, -10.15 to -0.64; P = .03). By 52 weeks, individuals with persistent ME also had poorer 100-week BCVA compared with individuals with dry macula (adjusted difference, -7.39; 95% CI, -11.72 to -3.05; P < .001) and recurrent ME (adjusted difference, -3.92; 95% CI, -8.05 to 0.20; P = .06). By 100 weeks, more eyes treated with bevacizumab had persistently wet macula than those treated with aflibercept (26 of 140 [18.6%] vs 7 of 134 [5.2%]; difference, 13.3%; 95% CI, 5.9 to 20.8; P < .001) or ranibizumab (11 of 137 [8%]; difference, 10.5%; 95% CI, 2.7 to 18.4; P = .01). CONCLUSIONS AND RELEVANCE: These findings suggest that attempts should be made to maintain persistently fluid-free macula for optimal visual acuity outcomes.
引用
- Gurudas S, Patrao N, Nicholson L, et al. Visual Outcomes Associated With Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated With Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial. JAMA Ophthalmol. 2022. PMID: 34989804. doi:10.1001/jamaophthalmol.2021.5619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。